- Home
- NVST vs RARE Comparison
NVST vs RARE Comparison
Compare NVST & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVST
- RARE
- Stock Information
- Founded
- NVST 2018
- RARE 2010
- Country
- NVST United States
- RARE United States
- Employees
- NVST N/A
- RARE N/A
- Industry
- NVST Medical/Dental Instruments
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NVST Health Care
- RARE Health Care
- Exchange
- NVST Nasdaq
- RARE Nasdaq
- Market Cap
- NVST 3.3B
- RARE 3.6B
- IPO Year
- NVST 2019
- RARE 2014
- Fundamental
- Price
- NVST $17.45
- RARE $36.61
- Analyst Decision
- NVST Hold
- RARE Strong Buy
- Analyst Count
- NVST 13
- RARE 15
- Target Price
- NVST $20.54
- RARE $95.93
- AVG Volume (30 Days)
- NVST 3.6M
- RARE 736.1K
- Earning Date
- NVST 04-30-2025
- RARE 05-01-2025
- Dividend Yield
- NVST N/A
- RARE N/A
- EPS Growth
- NVST N/A
- RARE N/A
- EPS
- NVST N/A
- RARE N/A
- Revenue
- NVST $2,510,600,000.00
- RARE $560,230,000.00
- Revenue This Year
- NVST $2.57
- RARE $19.15
- Revenue Next Year
- NVST $3.26
- RARE $32.11
- P/E Ratio
- NVST N/A
- RARE N/A
- Revenue Growth
- NVST N/A
- RARE 29.01
- 52 Week Low
- NVST $15.15
- RARE $36.71
- 52 Week High
- NVST $23.00
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- NVST 43.86
- RARE 32.96
- Support Level
- NVST $17.28
- RARE $36.71
- Resistance Level
- NVST $18.04
- RARE $39.21
- Average True Range (ATR)
- NVST 0.66
- RARE 1.33
- MACD
- NVST 0.15
- RARE -0.13
- Stochastic Oscillator
- NVST 66.25
- RARE 7.35
About NVST Envista Holdings Corporation
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.